Brokers Offer Predictions for AstraZeneca FY2025 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Zacks Research increased their FY2025 earnings per share estimates for shares of AstraZeneca in a report issued on Monday, February 3rd. Zacks Research analyst R. Department now expects that the company will earn $4.59 per share for the year, up from their previous estimate of $4.58. The consensus estimate for AstraZeneca’s current full-year earnings is $4.13 per share. Zacks Research also issued estimates for AstraZeneca’s Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.09 EPS.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the company earned $0.87 earnings per share.

Several other brokerages have also issued reports on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Down 1.3 %

AZN opened at $68.96 on Wednesday. The firm has a market capitalization of $213.85 billion, a P/E ratio of 33.00, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. AstraZeneca has a one year low of $60.47 and a one year high of $87.68. The company has a fifty day moving average price of $67.20 and a 200-day moving average price of $73.72. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

Hedge Funds Weigh In On AstraZeneca

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC lifted its position in AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after purchasing an additional 258,477 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of AstraZeneca by 8.7% in the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after buying an additional 1,522,715 shares during the period. Jennison Associates LLC raised its holdings in AstraZeneca by 3.1% during the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company’s stock valued at $1,011,037,000 after buying an additional 466,416 shares during the last quarter. Fisher Asset Management LLC boosted its position in AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after buying an additional 524,175 shares during the period. Finally, Manning & Napier Advisors LLC grew its holdings in AstraZeneca by 17.7% in the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock worth $245,407,000 after acquiring an additional 564,297 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.